Your browser doesn't support javascript.
loading
Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B.
Matsumoto, Akihiro; Yatsuhashi, Hiroshi; Nagaoka, Shinya; Suzuki, Yoshiyuki; Hosaka, Tetsuya; Tsuge, Masataka; Chayama, Kazuaki; Kanda, Tatsuo; Yokosuka, Osamu; Nishiguchi, Shuhei; Saito, Masaki; Miyase, Shiho; Kang, Jong-Hon; Shinkai, Noboru; Tanaka, Yasuhito; Umemura, Takeji; Tanaka, Eiji.
Afiliação
  • Matsumoto A; Department of Medicine, Shinshu University School of Medicine, Matsumoto.
  • Yatsuhashi H; The Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Omura.
  • Nagaoka S; The Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Omura.
  • Suzuki Y; Department of Hepatology, Toranomon Hospital, Tokyo.
  • Hosaka T; Department of Hepatology, Toranomon Hospital, Tokyo.
  • Tsuge M; Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima.
  • Chayama K; Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima.
  • Kanda T; Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba.
  • Yokosuka O; Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba.
  • Nishiguchi S; Division of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya.
  • Saito M; Division of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya.
  • Miyase S; Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital, Kumamoto.
  • Kang JH; Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo.
  • Shinkai N; Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Tanaka Y; Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Umemura T; Department of Medicine, Shinshu University School of Medicine, Matsumoto.
  • Tanaka E; Department of Medicine, Shinshu University School of Medicine, Matsumoto.
Hepatol Res ; 45(12): 1195-202, 2015 Dec.
Article em En | MEDLINE | ID: mdl-25594111
AIM: The factors associated with the outcome of sequential therapy with interferon-α (IFN-α) in order to halt nucleoside/nucleotide analog (NUC) maintenance treatment for chronic hepatitis B were analyzed. METHODS: A total of 50 patients with chronic hepatitis B who underwent IFN-α sequential therapy for cessation of NUC were enrolled retrospectively. The subjects received NUC plus IFN-α for 4 weeks followed by IFN-α alone for 20 weeks. Natural IFN-α of 6-MU doses was administrated three times a week. A successful response to NUC/IFN-α sequential therapy was defined as serum hepatitis B virus (HBV) DNA below 4.0 log copies/mL, serum alanine aminotransferase (ALT) below 30 IU/L, and hepatitis B e-antigen negativity at 24 months after completing the treatment. RESULTS: Multivariate analysis revealed that hepatitis B surface antigen (HBsAg) of 3.0 log U/mL or more (P < 0.002) and hepatitis B core-related antigen (hepatitis B core-related antigen [HBcrAg]) of 4.5 log U/mL or more (P < 0.003) at the start of IFN-α administration were significant factors associated with a 24-month non-response. Maximal levels of ALT and HBV DNA during the follow-up period after completing IFN-α therapy were significantly related (P < 0.001), and receiver operating characteristic analysis showed that both maximal ALT (P < 0.001) and HBV DNA (P < 0.001) were significantly related to the final 24-month response. CONCLUSION: The combinational use of HBsAg and HBcrAg levels may be useful to predict the 24-month outcome of NUC/IFN-α sequential therapy. Maximal levels of ALT and HBV DNA during post-treatment follow-up may also help monitor responses to IFN-α sequential therapy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article